2026 ICD-10-CM Diagnosis Code Q82.1Xeroderma pigmentosum

ICD-10-CM Codes›Q00-Q99›Q80-Q89›Q82

ICD-10-CM Q82.1
CMSSource: CMS FY 2026 ICD-10-CM dataset · Effective Oct 1, 2025 – Sep 30, 2026

Q82.1 is a billable ICD-10-CM diagnosis code for xeroderma pigmentosum. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 606 through 607. The code is exempt from POA reporting. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Other specified and unspecified congenital anomalies.

Code Identity

ICD-10-CM Code
Q82.1
Billable Status
Yes — Valid for Submission
Code Describes
Xeroderma pigmentosum
Short Description
Xeroderma pigmentosum
Same as the full description in the CMS dataset.
Parent Code
Q82
Other congenital malformations of skin

Code Classification

ChapterQ00-Q99Congenital malformations, deformations and chromosomal abnormalities
SectionQ80-Q89Other congenital malformations
CategoryQ82Other congenital malformations of skin
This CodeQ82.1Xeroderma pigmentosum

Present on Admission (POA)Billing

Q82.1 is exempt from POA reporting on inpatient claims to general acute care hospitals. Review other POA exempt codes.

Approximate SynonymsGuidance

Alternate terms and clinical phrases that map to this code.

  • Cockayne syndrome
  • Disorder of central nervous system due to xeroderma pigmentosum
  • Multiple malformation syndrome with senile-like appearance
  • Non-neurologic xeroderma pigmentosum
  • Xeroderma pigmentosum
  • Xeroderma pigmentosum and Cockayne syndrome complex
  • Xeroderma pigmentosum, group A
  • Xeroderma pigmentosum, group B
  • Xeroderma pigmentosum, group C
  • Xeroderma pigmentosum, group D
  • Xeroderma pigmentosum, group E
  • Xeroderma pigmentosum, group F
  • Xeroderma pigmentosum, group G
  • Xeroderma pigmentosum, variant form

Index to Diseases and InjuriesGuidance

Alphabetical index entries that point to this code.

External Cause of Injuries IndexGuidance

References for this code in the External Cause of Injuries Index.

    • Atrophoderma, atrophodermia(of)
      • pigmentosum
    • Epitheliomatosis pigmented
    • Kaposi's
      • dermatosis (xeroderma pigmentosum)
    • Melanosis
      • lenticularis progressiva
    • Xeroderma
      • pigmentosum

Clinical ClassificationClinical

AHRQ’s CCSR groups this code into broader clinical categories.

CCSR MAL010
Other specified and unspecified congenital anomalies
Default principal diagnosis: inpatient Yes · outpatient Yes

Clinical InformationClinical

  • Xeroderma Pigmentosum

    a rare, pigmentary, and atrophic autosomal recessive disease. it is manifested as an extreme photosensitivity to ultraviolet rays as the result of a deficiency in the enzyme that permits excisional repair of ultraviolet-damaged dna.

  • Xeroderma Pigmentosum Group A Protein

    a zinc finger motif protein that recognizes and interacts with damaged dna. it is a dna-binding protein that plays an essential role in nucleotide excision repair. mutations in this protein are associated with the most severe form of xeroderma pigmentosum.

  • Xeroderma Pigmentosum Group D Protein

    a dna helicase that is a component of transcription factor tfiih. it plays an essential role in nucleotide excision repair, and mutations in this protein are associated with xeroderma pigmentosum.

  • Cockayne Syndrome

    a syndrome characterized by multiple system abnormalities including dwarfism; photosensitivity disorders; premature aging; and hearing loss. it is caused by mutations of a number of autosomal recessive genes encoding proteins that involve transcriptional-coupled dna repair processes. cockayne syndrome is classified by the severity and age of onset. type i (classical; csa) is early childhood onset in the second year of life; type ii (congenital; csb) is early onset at birth with severe symptoms; type iii (xeroderma pigmentosum; xp) is late childhood onset with mild symptoms.

Patient EducationClinical

Skin Conditions

Your skin is your body's largest organ. It covers the entire outside of your body. There are many ways that your skin protects your body and helps keep you healthy. For example, it:

The full article covers:

  • What does your skin do?
  • What problems and conditions can affect your skin?
  • How can I keep my skin healthy?

Read the full article at MedlinePlus

Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.

Convert Q82.1 to ICD-9-CMHistory

The closest ICD-9-CM equivalents under the General Equivalence Mappings.

ICD-9-CM
757.33 Cong skin pigment anomal
Approximate The match is approximate rather than exact.

Code HistoryHistory

FY 2016AddedAdded to the ICD-10-CM code setEffective October 1, 2015, the first year of ICD-10-CM.
FY 2017–2025No changes
FY 2026CurrentCurrent code set, no changesEffective October 1, 2025 through September 30, 2026.

Questions About Q82.1Overview

Is Q82.1 (Other congenital malformations of skin) a billable code?

Yes. This is a billable ICD-10-CM code, specific enough to report xeroderma pigmentosum on HIPAA-covered claims from October 1, 2025 through September 30, 2026.

What MS-DRG does Q82.1 group to?

When xeroderma pigmentosum is the principal diagnosis on an inpatient stay, it groups to MS-DRG 606, 607, with relative weights from 0.9064 to 1.5132 depending on complications. Higher weights mean higher Medicare reimbursement.

Is Q82.1 exempt from POA reporting?

Yes. CMS lists this code among those exempt from present on admission reporting, so hospitals do not assign a POA indicator for xeroderma pigmentosum on inpatient claims.

What is the ICD-9 equivalent of Q82.1?

Under the General Equivalence Mappings, xeroderma pigmentosum converts to ICD-9-CM 757.33 (cong skin pigment anomal). The mapping is approximate, so confirm the match fits the documentation.

Footnotes

[1] Chronic - a chronic condition code indicates a condition lasting 12 months or longer and its effect on the patient based on one or both of the following criteria:

  • The condition results in the need for ongoing intervention with medical products,treatment, services, and special equipment
  • The condition places limitations on self-care, independent living, and social interactions.